tiprankstipranks
Trending News
More News >
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Advertisement

Protagonist Therapeutics (PTGX) AI Stock Analysis

Compare
689 Followers

Top Page

PTGX

Protagonist Therapeutics

(NASDAQ:PTGX)

Rating:60Neutral
Price Target:
$54.00
▲(0.48%Upside)
Protagonist Therapeutics' overall score is driven by a mix of financial performance and technical analysis. The positive trend in stock price is offset by financial instability, high valuation metrics, and the absence of consistent revenue growth.
Positive Factors
Obesity Treatment Development
The new development candidate PN-477 for obesity is expected to be highly competitive due to its engineered receptor binding and strong lean mass preservation.
Psoriasis Study Results
PTGX and partner JNJ announced positive data from the two Ph3 ICONIC ADVANCE 1&2 studies that compared icotrokinra (JNJ-2113) vs. deucravacitinib (Sotyktu) head-to-head, showing statistical superiority to Sotyktu at Weeks 16 and 24.
Psoriasis Treatment Efficacy
Icotrokinra is expected to emerge as the preferred oral treatment option in psoriasis due to its mix of efficacy and safety.
Negative Factors
Competition in Obesity Treatment
PN-477 is set to compete against retatrutide, the current leader in efficacy for obesity treatment, which could pose challenges in gaining market share.
Regulatory and Financial Milestones
PTGX is entitled to $35M upon the NDA filing for icotrokinra and $50M upon FDA approval, indicating significant financial dependency on regulatory success.

Protagonist Therapeutics (PTGX) vs. SPDR S&P 500 ETF (SPY)

Protagonist Therapeutics Business Overview & Revenue Model

Company DescriptionProtagonist Therapeutics (PTGX) is a biopharmaceutical company dedicated to developing and advancing peptide-based therapeutics for the treatment of various diseases. The company focuses on leveraging its proprietary technology platform to design and develop novel drugs that target specific biological pathways in the fields of hematology and immunology. Protagonist Therapeutics is committed to addressing unmet medical needs through its innovative pipeline of drug candidates.
How the Company Makes MoneyProtagonist Therapeutics primarily makes money through the development and commercialization of its peptide-based therapeutics. The company generates revenue through partnerships and collaborations with larger pharmaceutical companies, which may involve licensing agreements, milestone payments, and royalties from the sales of successfully developed products. Additionally, Protagonist Therapeutics may receive funding from research grants and government initiatives aimed at supporting innovative drug development. The company's revenue model is heavily reliant on the successful progression of its drug candidates through clinical trials and their eventual approval and commercialization in the market.

Protagonist Therapeutics Financial Statement Overview

Summary
Protagonist Therapeutics shows a mixed financial picture with improved profitability and cash flow management. However, the lack of consistent revenue growth and past financial instability are concerns. The company has a strong equity position but needs to stabilize revenue streams.
Income Statement
35
Negative
Protagonist Therapeutics has experienced significant fluctuations in its revenue, with a notable decline to zero in the most recent year, indicating potential instability in its business operations. The net profit margin is currently positive due to a reversal in earnings, but the lack of consistent revenue growth is a concern. EBIT and EBITDA margins have improved significantly, suggesting better cost management.
Balance Sheet
60
Neutral
The company has a strong equity position with a positive stockholders' equity and a low debt-to-equity ratio, indicating financial stability. The equity ratio suggests a healthy proportion of assets funded by equity rather than debt. However, the industry-standard high liabilities in previous years suggest a history of financial risk.
Cash Flow
50
Neutral
Protagonist Therapeutics shows positive free cash flow and an improved operating cash flow, indicating better cash management. However, the volatility in free cash flow growth suggests potential cash flow instability. The operating cash flow to net income ratio is favorable, indicating effective conversion of earnings to cash.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue434.43M60.00M26.58M27.36M28.63M
Gross Profit431.47M60.00M25.55M24.58M28.63M
EBITDA252.84M-90.34M-131.37M-123.07M-63.66M
Net Income275.19M-78.95M-123.41M-122.63M-66.15M
Balance Sheet
Total Assets744.73M357.95M247.93M347.69M324.47M
Cash, Cash Equivalents and Short-Term Investments418.91M341.62M237.35M326.90M307.81M
Total Debt10.87M1.14M3.66M5.86M5.96M
Total Liabilities69.43M21.27M784.68M47.67M44.86M
Stockholders Equity675.29M336.68M-536.75M-409.36M-283.81M
Cash Flow
Free Cash Flow182.80M-70.84M-108.93M-108.97M-72.95M
Operating Cash Flow184.15M-70.24M-108.14M-107.86M-72.48M
Investing Cash Flow-299.48M-39.26M91.47M-15.86M-90.97M
Financing Cash Flow25.85M170.48M18.84M129.92M247.63M

Protagonist Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price53.74
Price Trends
50DMA
51.73
Positive
100DMA
49.26
Positive
200DMA
45.27
Positive
Market Momentum
MACD
0.79
Positive
RSI
51.03
Neutral
STOCH
45.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTGX, the sentiment is Positive. The current price of 53.74 is above the 20-day moving average (MA) of 53.65, above the 50-day MA of 51.73, and above the 200-day MA of 45.27, indicating a bullish trend. The MACD of 0.79 indicates Positive momentum. The RSI at 51.03 is Neutral, neither overbought nor oversold. The STOCH value of 45.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTGX.

Protagonist Therapeutics Risk Analysis

Protagonist Therapeutics disclosed 53 risk factors in its most recent earnings report. Protagonist Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Protagonist Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$3.89B16.9437.24%22.42%
64
Neutral
$5.88B-19.71%-86.13%-67.29%
61
Neutral
$4.89B-58.66%42.77%-51.27%
60
Neutral
$3.36B71.248.99%-34.02%-65.83%
53
Neutral
$3.75B-19.99%-23.84%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
50
Neutral
$3.77B-106.71%-22.34%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PTGX
Protagonist Therapeutics
53.74
13.46
33.42%
ACAD
ACADIA Pharmaceuticals
23.05
3.91
20.43%
VKTX
Viking Therapeutics
33.50
-32.48
-49.23%
MRUS
Merus
65.69
11.50
21.22%
CRSP
Crispr Therapeutics AG
66.06
8.14
14.05%
SRRK
Scholar Rock Holding
39.11
29.83
321.44%

Protagonist Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Protagonist Therapeutics Stockholders Approve Key Proposals
Neutral
Jun 26, 2025

At the Annual Meeting, Protagonist Therapeutics‘ stockholders voted on three key proposals. The first proposal involved electing two Class III directors, Harold E. Selick, Ph.D., and Bryan Giraudo, to serve until the 2028 Annual Meeting, both of whom were elected. The second proposal, regarding the approval of executive compensation, was passed. The third proposal, ratifying Ernst & Young LLP as the company’s independent auditor for the fiscal year ending December 31, 2025, was also approved.

The most recent analyst rating on (PTGX) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Protagonist Therapeutics stock, see the PTGX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 05, 2025